EGFR and non-small cell lung carcinoma: NCT02296125 (FLAURA, PI: Yi-long Wu, Guangdong General Hospital, China) is a double-blind, phase III study designed to assess the efficacy and safety of osimertinib versus a standard of care EGFR TKI (gefitinib 250 mg or erlotinib 150 mg, once daily) in treatment-naïve patients with locally advanced or metastatic EGFR-mutant NSCLC.